Company profile: Landos Biopharma
1.1 - Company Overview
Company description
- Provider of oral, first-in-class, locally acting small-molecule therapeutics for autoimmune diseases. Pipeline: NX-13 (NLRX1) for ulcerative colitis and Crohn’s; LABP-66 (NLRX1) for multiple sclerosis and neurodegenerative disorders; LABP-73 (NLRX1) for asthma and eosinophilic disorders; LABP-69 (PLXDC2) for rheumatoid arthritis, ulcerative colitis, and Crohn’s.
Products and services
- NX-13: A first-in-class oral therapeutic candidate targeting NLRX1 to modulate gastrointestinal immune responses for ulcerative colitis and Crohn’s disease
- LABP-69: An oral small-molecule PLXDC2 pathway agonist in development intended to modulate immune responses in rheumatoid arthritis, ulcerative colitis, and Crohn’s disease
- LABP-66: An oral small-molecule NLRX1 pathway agonist in development for treating multiple sclerosis and neurodegenerative disorders by modulating immune activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Landos Biopharma
Arkuda Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery and development for neurodegenerative diseases, pursuing treatments to alter the course of Alzheimer’s, Parkinson’s, and frontotemporal dementia by leveraging lysosomal biology to target cellular recycling and homeostasis, informed by novel insights into regulation of proteins essential for lysosomal function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arkuda Therapeutics company profile →
Gabather
HQ: Sweden
Website
- Description: Provider of research and development of innovative therapeutics for neuropsychiatric disorders, focusing on pro-cognitive drug candidates targeting GABAA receptor systems for central nervous system disorders, including GT-002, a small-molecule GABAA receptor PAM in clinical development to improve learning and memory, reduce anxiety, and promote social interaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gabather company profile →
Mitokinin
HQ: United States
Website
- Description: Provider of biotechnology R&D focused on medicinal chemistry to generate kinetin analogs optimized for activating PINK1, with plans to develop these analogs or optimized variants to treat Parkinson's disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitokinin company profile →
Ionix Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of discovery and development of new analgesic medicines for the treatment of acute and chronic pain. Based in Cambridge, UK, Ionix Pharmaceuticals leverages proprietary drug targets and state-of-the-art chemistry to alleviate pain associated with trauma and operative procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ionix Pharmaceuticals company profile →
Levicept
HQ: United Kingdom
Website
- Description: Provider of biological therapies for chronic pain, including LEVI-04 (p75NTR-Fc) for knee osteoarthritis that modulates the neurotrophin pathway to minimize side effects associated with anti-NGF antibodies, and a Phase II randomized, double-blind, placebo-controlled clinical trial assessing its efficacy, safety, and tolerability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Levicept company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Landos Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Landos Biopharma
2.2 - Growth funds investing in similar companies to Landos Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Landos Biopharma
4.2 - Public trading comparable groups for Landos Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →